It was great to talk with Prof. Maarten Boers (VU University Medical Center, Amsterdam, The Netherlands) to discuss the responsiveness and high discriminative validity of GLOESS and clinical outcomes of synovitis in PsA patients treated with secukinumab from the ULTIMATE Trial.
The abstract ‘Responsiveness of Ultrasound Synovitis and Clinical Outcomes in Psoriatic Arthritis Treated with Secukinumab: Data from the ULTIMATE Trial.‘ (POS0197), was presented at the European Congress of Rheumatology 2021, 2-5 June 2021.
- Could you tell us a little about Power Doppler ultrasonography and its advantages in the evaluation of synovitis in psoriatic arthritis (PsA)? (0:43)
- What were the objectives and design of the ULTIMATE clinical trial? (1:50)
- What were the findings of the study? (2:42)
- What conclusions were reached about the responsiveness and high discriminative validity of GLOESS in PsA? (3:39)
- How do you anticipate the role of ultrasound in PSA developing in the future? (5:04)
Disclosures: Maarten Boers has disclosures with BMS, Pfizer and Novartis.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of EULAR 2021 (Virtual).
Share this Video
Related Videos In Psoriatic Arthritis
Michaela Koehm, ACR 2021: Methotrexate Effect on bDMARDs in the Treatment of Active PsA
We were delighted to speak with Dr. Michaela Koehm (Goethe University, Frankfurt am Main, Germany) to discuss her trial investigating the effect of methotrexate on ustekinumab treatment for active psoriatic arthritis. The abstract ‘Neither Add-on nor Withdrawal of Methotrexate Impacts Efficacy of IL12/23 Inhibition in Active PsA: Data from a Multicenter Investigator-initiated Randomized Placebo-controlled Clinical […]
Atul Deodhar, ACR 2021: Efficacy of Deucravacitinib by Baseline DMARD Use in Psoriatic Arthritis
It was a pleasure to discuss with Prof. Atul Deodhar (Oregon Health & Science University, Portland, OR, USA) the results from the further exploratory analysis of the phase 2 trial (NCT03881059) investigating the TYK2 inhibitor, deucravacitinib, in patients with psoriatic arthritis treated with and without background conventional synthetic DMARDs. This information is brought to you […]
Merav Lidar, ACR 2021: Efficacy and Safety of Risankizumab in Psoriatic Arthritis
Prof. Merav Lidar (Sheba Medical Center, Tel Hashomer, Israel) kindly took the time to discuss the 24-week efficacy and safety results from the KEEPsaKE2 trial (NCT03671148). This phase 3 randomized, double-blind trial investigated the humanized immunoglobulin G1 monoclonal antibody, risankizumab, in adults with psoriatic arthritis (PsA). This information is brought to you by Touch Medical […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!